We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$475M
AUM Growth
+$226M
Cap. Flow
+$193M
Cap. Flow %
40.57%
Top 10 Hldgs %
41.72%
Holding
154
New
62
Increased
25
Reduced
13
Closed
48

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$7.96M
2
AMGN icon
Amgen
AMGN
+$5.99M
3
AZTA icon
Azenta
AZTA
+$5.35M
4
ESTA icon
Establishment Labs
ESTA
+$5.33M
5
CNC icon
Centene
CNC
+$5.26M

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$3.59M
2
HOLX
Hologic
HOLX
+$3.48M
3
ATHN
Athenahealth, Inc.
ATHN
+$3.34M
4
AGN
Allergan plc
AGN
+$3.33M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 35.48%
2 Industrials 0.59%
3 Technology 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVC
76
DELISTED
Invacare Corporation
IVC
$1.46M 0.31%
100,000
-22,735
-19% -$377K
NSTG
77
CALL
DELISTED
NanoString Technologies, Inc.
NSTG
$1.34M 0.28%
+75,000
New +$1.1M
ARVN icon
78
Arvinas
ARVN
$588M
$1.26M 0.27%
+75,000
New +$1.23M
BSTC
79
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.18M 0.25%
+20,160
New +$1.03M
ARAY icon
80
CALL
Accuray
ARAY
$34.6M
$1.13M 0.24%
250,000
-300,000
-55% -$1.18M
LAB icon
81
CALL
Standard BioTools
LAB
$309M
$1.12M 0.24%
+150,000
New +$1.07M
PRQR icon
82
ProQR Therapeutics
PRQR
$271M
$1.1M 0.23%
56,803
-214,356
-79% -$2.28M
GRTS
83
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.07M 0.22%
+75,000
New +$1.07M
CLLS
84
Cellectis
CLLS
$291M
$1M 0.21%
35,437
+437
+1% +$12.6K
RIGL icon
85
Rigel Pharmaceuticals
RIGL
$785M
$971K 0.2%
30,249
-24,751
-45% -$743K
OBSV
86
DELISTED
ObsEva SA Ordinary Shares
OBSV
$913K 0.19%
50,622
-39,378
-44% -$579K
RNAC icon
87
Cartesian Therapeutics
RNAC
$260M
$905K 0.19%
+1,940
New +$779K
SPPI
88
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$840K 0.18%
+50,000
New +$1.08M
SNDX icon
89
CALL
Syndax Pharmaceuticals
SNDX
$1.81B
$808K 0.17%
+100,000
New +$713K
SNDX icon
90
Syndax Pharmaceuticals
SNDX
$1.81B
$808K 0.17%
+100,000
New +$713K
MDGL icon
91
Madrigal Pharmaceuticals
MDGL
$12.4B
$793K 0.17%
3,702
-9,398
-72% -$2.36M
OTIC
92
DELISTED
Otonomy, Inc.
OTIC
$791K 0.17%
287,657
+204,863
+247% +$657K
BCRX icon
93
BioCryst Pharmaceuticals
BCRX
$2.64B
$773K 0.16%
+101,245
New +$680K
DRNA
94
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$772K 0.16%
+50,622
New +$737K
CPRX
95
DELISTED
Catalyst Pharmaceutical
CPRX
$765K 0.16%
202,489
+52,489
+35% +$164K
INCY icon
96
CALL
Incyte
INCY
$24.5B
$691K 0.15%
10,000
– –
YMAB
97
DELISTED
Y-mAbs Therapeutics
YMAB
$594K 0.13%
+22,350
New +$568K
OCUL icon
98
Ocular Therapeutix
OCUL
$2.14B
$592K 0.12%
+86,058
New +$540K
FOLD
99
DELISTED
Amicus Therapeutics
FOLD
$551K 0.12%
+45,560
New +$637K
ITCI
100
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$543K 0.11%
25,000
– –
2 3
4
5 6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Pura Vida Investments held 154 positions worth $475M, up 91% from $250M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Pura Vida Investments deployed $193M of net new capital in Q3 2018, opening 62 new positions and adding to 25 existing holdings. Its largest new stake was Amgen: 30,373 shares worth $6.3M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 37% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $2.36M trimmed.

  • Pura Vida Investments's largest Q3 2018 buy was Amgen: 30,373 shares worth $6.3M.
  • Pura Vida Investments added most to Boston Scientific in Q3 2018, an estimated $7.96M increase.
  • Pura Vida Investments's biggest Q3 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $2.36M.
  • Pura Vida Investments fully exited Sientra, Inc. in Q3 2018, selling an estimated $3.59M.
  • Pura Vida Investments's ten largest holdings make up 42% of its $475M portfolio in Q3 2018.
  • Pura Vida Investments opened 62 new positions and closed 48 in Q3 2018.
  • Pura Vida Investments's portfolio value rose 91% quarter-over-quarter to $475M.

Based on Pura Vida Investments's 13F filing for Q3 2018, filed 14 Nov 2018.